Difference between revisions of "Cabazitaxel (Jevtana)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
|||
| Line 25: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Taxanes]] | [[Category:Taxanes]] | ||
Revision as of 17:44, 25 July 2017
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabazitaxel (Jevtana) package insert[1]
- Cabazitaxel (Jevtana) patient drug information (Chemocare)[4]
- Cabazitaxel (Jevtana) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/17/2010: Initial FDA approval "in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen."
Also known as
XRP6258, TXD258, or RPR116258A.